Advanced interstitial chemotherapy for treating malignant glioma

Yuan-Yun Tseng, Yi Chuan Kau, Shih Jung Liu

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: Glioblastoma multiforme (GBM) is the most prevalent primary neoplasm of the brain. Moreover, the prognosis of patients with GBM has been poor, with almost uniform progressive neurological impairment and rapid death. Despite the availability of multimodal treatments through surgery, focal radiation, and chemotherapy, no major progress has been reported until recently. Area covered: The development of interstitial biodegradable carmustine wafers (Gliadel) for treating selected patients with malignant gliomas has resulted in marginal survival benefits in such patients (only approximately 2 months longer than that of those who did not receive the treatment). Therefore, this study summarizes several recent representative studies, presents emerging studies, and highlights the directions for additional developments in this area. An overview of the current knowledge of preclinical developments, efficacy and safety observed in clinical trials and practice following drug approval, and future avenues of research is imperative. Expert opinion: Studies are being conducted to improve the efficacy of interstitial chemotherapy by using nanobiotechnology and polymeric material science in addition to different chemotherapeutic, antiangiogenesic, and gene therapy agents and growth factors. Nanocarrier-based noninvasive techniques may have considerable potential to enhance the efficacy of GBM treatment.

Original languageEnglish
Pages (from-to)1533-1544
Number of pages12
JournalExpert Opinion on Drug Delivery
Volume13
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Glioblastoma
Glioma
Drug Therapy
Drug Approval
Carmustine
Combined Modality Therapy
Expert Testimony
Brain Neoplasms
Genetic Therapy
Intercellular Signaling Peptides and Proteins
Clinical Trials
Radiation
Safety
Survival
Therapeutics
Research

Keywords

  • Blood–brain barrier
  • carmustine wafers (Gliadel)
  • interstitial chemotherapy
  • local delivery
  • malignant gliomas
  • nanobiotechnology

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Advanced interstitial chemotherapy for treating malignant glioma. / Tseng, Yuan-Yun; Kau, Yi Chuan; Liu, Shih Jung.

In: Expert Opinion on Drug Delivery, Vol. 13, No. 11, 01.11.2016, p. 1533-1544.

Research output: Contribution to journalReview article

Tseng, Yuan-Yun ; Kau, Yi Chuan ; Liu, Shih Jung. / Advanced interstitial chemotherapy for treating malignant glioma. In: Expert Opinion on Drug Delivery. 2016 ; Vol. 13, No. 11. pp. 1533-1544.
@article{8dad40bab79d461ea4e5fcff0c8a5b7c,
title = "Advanced interstitial chemotherapy for treating malignant glioma",
abstract = "Introduction: Glioblastoma multiforme (GBM) is the most prevalent primary neoplasm of the brain. Moreover, the prognosis of patients with GBM has been poor, with almost uniform progressive neurological impairment and rapid death. Despite the availability of multimodal treatments through surgery, focal radiation, and chemotherapy, no major progress has been reported until recently. Area covered: The development of interstitial biodegradable carmustine wafers (Gliadel) for treating selected patients with malignant gliomas has resulted in marginal survival benefits in such patients (only approximately 2 months longer than that of those who did not receive the treatment). Therefore, this study summarizes several recent representative studies, presents emerging studies, and highlights the directions for additional developments in this area. An overview of the current knowledge of preclinical developments, efficacy and safety observed in clinical trials and practice following drug approval, and future avenues of research is imperative. Expert opinion: Studies are being conducted to improve the efficacy of interstitial chemotherapy by using nanobiotechnology and polymeric material science in addition to different chemotherapeutic, antiangiogenesic, and gene therapy agents and growth factors. Nanocarrier-based noninvasive techniques may have considerable potential to enhance the efficacy of GBM treatment.",
keywords = "Blood–brain barrier, carmustine wafers (Gliadel), interstitial chemotherapy, local delivery, malignant gliomas, nanobiotechnology",
author = "Yuan-Yun Tseng and Kau, {Yi Chuan} and Liu, {Shih Jung}",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/17425247.2016.1193153",
language = "English",
volume = "13",
pages = "1533--1544",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Advanced interstitial chemotherapy for treating malignant glioma

AU - Tseng, Yuan-Yun

AU - Kau, Yi Chuan

AU - Liu, Shih Jung

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: Glioblastoma multiforme (GBM) is the most prevalent primary neoplasm of the brain. Moreover, the prognosis of patients with GBM has been poor, with almost uniform progressive neurological impairment and rapid death. Despite the availability of multimodal treatments through surgery, focal radiation, and chemotherapy, no major progress has been reported until recently. Area covered: The development of interstitial biodegradable carmustine wafers (Gliadel) for treating selected patients with malignant gliomas has resulted in marginal survival benefits in such patients (only approximately 2 months longer than that of those who did not receive the treatment). Therefore, this study summarizes several recent representative studies, presents emerging studies, and highlights the directions for additional developments in this area. An overview of the current knowledge of preclinical developments, efficacy and safety observed in clinical trials and practice following drug approval, and future avenues of research is imperative. Expert opinion: Studies are being conducted to improve the efficacy of interstitial chemotherapy by using nanobiotechnology and polymeric material science in addition to different chemotherapeutic, antiangiogenesic, and gene therapy agents and growth factors. Nanocarrier-based noninvasive techniques may have considerable potential to enhance the efficacy of GBM treatment.

AB - Introduction: Glioblastoma multiforme (GBM) is the most prevalent primary neoplasm of the brain. Moreover, the prognosis of patients with GBM has been poor, with almost uniform progressive neurological impairment and rapid death. Despite the availability of multimodal treatments through surgery, focal radiation, and chemotherapy, no major progress has been reported until recently. Area covered: The development of interstitial biodegradable carmustine wafers (Gliadel) for treating selected patients with malignant gliomas has resulted in marginal survival benefits in such patients (only approximately 2 months longer than that of those who did not receive the treatment). Therefore, this study summarizes several recent representative studies, presents emerging studies, and highlights the directions for additional developments in this area. An overview of the current knowledge of preclinical developments, efficacy and safety observed in clinical trials and practice following drug approval, and future avenues of research is imperative. Expert opinion: Studies are being conducted to improve the efficacy of interstitial chemotherapy by using nanobiotechnology and polymeric material science in addition to different chemotherapeutic, antiangiogenesic, and gene therapy agents and growth factors. Nanocarrier-based noninvasive techniques may have considerable potential to enhance the efficacy of GBM treatment.

KW - Blood–brain barrier

KW - carmustine wafers (Gliadel)

KW - interstitial chemotherapy

KW - local delivery

KW - malignant gliomas

KW - nanobiotechnology

UR - http://www.scopus.com/inward/record.url?scp=84991396109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991396109&partnerID=8YFLogxK

U2 - 10.1080/17425247.2016.1193153

DO - 10.1080/17425247.2016.1193153

M3 - Review article

C2 - 27248137

AN - SCOPUS:84991396109

VL - 13

SP - 1533

EP - 1544

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 11

ER -